CN1169527C - 用5-氮杂喹喔啉类化合物体外调节丝氨酸/苏氨酸蛋白激酶功能的方法 - Google Patents

用5-氮杂喹喔啉类化合物体外调节丝氨酸/苏氨酸蛋白激酶功能的方法 Download PDF

Info

Publication number
CN1169527C
CN1169527C CNB988099403A CN98809940A CN1169527C CN 1169527 C CN1169527 C CN 1169527C CN B988099403 A CNB988099403 A CN B988099403A CN 98809940 A CN98809940 A CN 98809940A CN 1169527 C CN1169527 C CN 1169527C
Authority
CN
China
Prior art keywords
azaquinoxaline
phenyl
hydroxyphenyl
cell
azepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988099403A
Other languages
English (en)
Chinese (zh)
Other versions
CN1274284A (zh
Inventor
G
G·迈克马弘
ж�
B·库茨切尔
E·冈瑟
H·艾普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Asta Medica GmbH
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH, Zentaris AG filed Critical Asta Medica GmbH
Publication of CN1274284A publication Critical patent/CN1274284A/zh
Application granted granted Critical
Publication of CN1169527C publication Critical patent/CN1169527C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988099403A 1997-10-06 1998-10-05 用5-氮杂喹喔啉类化合物体外调节丝氨酸/苏氨酸蛋白激酶功能的方法 Expired - Fee Related CN1169527C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06
US60/061,123 1997-10-06

Publications (2)

Publication Number Publication Date
CN1274284A CN1274284A (zh) 2000-11-22
CN1169527C true CN1169527C (zh) 2004-10-06

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988099403A Expired - Fee Related CN1169527C (zh) 1997-10-06 1998-10-05 用5-氮杂喹喔啉类化合物体外调节丝氨酸/苏氨酸蛋白激酶功能的方法

Country Status (30)

Country Link
US (2) US6180631B1 (https=)
EP (1) EP1028729B1 (https=)
JP (1) JP2001518496A (https=)
KR (1) KR100633270B1 (https=)
CN (1) CN1169527C (https=)
AR (1) AR013542A1 (https=)
AT (1) ATE336250T1 (https=)
AU (1) AU757585B2 (https=)
BG (1) BG64969B1 (https=)
BR (1) BR9814814A (https=)
CA (1) CA2306257C (https=)
CY (1) CY1106223T1 (https=)
CZ (1) CZ298775B6 (https=)
DE (1) DE69835612T2 (https=)
DK (1) DK1028729T3 (https=)
ES (1) ES2268791T3 (https=)
HU (1) HUP0100302A3 (https=)
IL (2) IL135103A0 (https=)
MX (1) MXPA03011007A (https=)
NO (1) NO316598B1 (https=)
NZ (1) NZ503431A (https=)
PL (1) PL192039B1 (https=)
PT (1) PT1028729E (https=)
RU (1) RU2223753C2 (https=)
SK (1) SK4722000A3 (https=)
TR (2) TR200000906T2 (https=)
TW (1) TWI245765B (https=)
UA (1) UA71555C2 (https=)
WO (1) WO1999017759A2 (https=)
ZA (1) ZA988961B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358552A (zh) * 2013-05-11 2016-02-24 默克专利股份公司 芳基喹唑啉

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
WO2001032658A1 (en) * 1999-11-02 2001-05-10 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
AU2003270727A1 (en) * 2002-09-17 2004-04-08 Luna Innovations, Inc. Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
AU2004240747B2 (en) 2003-05-23 2008-01-03 Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
RU2655604C2 (ru) 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX373150B (es) 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
RU2743074C2 (ru) 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358552A (zh) * 2013-05-11 2016-02-24 默克专利股份公司 芳基喹唑啉
CN105358552B (zh) * 2013-05-11 2018-04-27 默克专利股份公司 芳基喹唑啉

Also Published As

Publication number Publication date
BR9814814A (pt) 2000-10-03
ZA988961B (en) 1999-10-04
MXPA03011007A (es) 2004-02-27
TR200100385T2 (tr) 2002-06-21
CA2306257A1 (en) 1999-04-15
JP2001518496A (ja) 2001-10-16
PT1028729E (pt) 2006-12-29
TR200000906T2 (tr) 2000-11-21
CY1106223T1 (el) 2011-06-08
BG104392A (en) 2000-12-29
EP1028729B1 (en) 2006-08-16
CA2306257C (en) 2007-09-25
ATE336250T1 (de) 2006-09-15
SK4722000A3 (en) 2002-06-04
DE69835612D1 (de) 2006-09-28
NO316598B1 (no) 2004-03-01
KR100633270B1 (ko) 2006-10-16
IL135103A0 (en) 2001-05-20
US6727252B1 (en) 2004-04-27
AR013542A1 (es) 2000-12-27
CN1274284A (zh) 2000-11-22
DE69835612T2 (de) 2007-08-16
NO20001748L (no) 2000-04-05
HUP0100302A3 (en) 2006-03-28
BG64969B1 (bg) 2006-11-30
WO1999017759A3 (en) 2000-01-06
NZ503431A (en) 2002-07-26
PL192039B1 (pl) 2006-08-31
US6180631B1 (en) 2001-01-30
ES2268791T3 (es) 2007-03-16
AU9514198A (en) 1999-04-27
CZ298775B6 (cs) 2008-01-23
UA71555C2 (en) 2004-12-15
WO1999017759A2 (en) 1999-04-15
NO20001748D0 (no) 2000-04-05
PL339860A1 (en) 2001-01-15
KR20010030934A (ko) 2001-04-16
HUP0100302A2 (hu) 2001-06-28
RU2223753C2 (ru) 2004-02-20
IL135103A (en) 2007-06-17
TWI245765B (en) 2005-12-21
CZ20001129A3 (cs) 2000-10-11
HK1031836A1 (en) 2001-06-29
DK1028729T3 (da) 2006-12-11
EP1028729A2 (en) 2000-08-23
AU757585B2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
CN1169527C (zh) 用5-氮杂喹喔啉类化合物体外调节丝氨酸/苏氨酸蛋白激酶功能的方法
CN1167420C (zh) 用于调制丝氨酸/苏氨酸蛋白激酶功能的氮杂苯并咪唑类化合物
CN1043639C (zh) 新的哌啶化合物、其制备方法和含有它们的药用组合物
CN1134438C (zh) 二环杂芳族化合物、其制备方法以及用途
CN1149085C (zh) 用取代杂环脲抑制raf激酶
CN1231471C (zh) 4－氨基－5－氰基－2－苯胺基－嘧啶衍生物和它们作为细胞周期激酶的抑制剂的用途
CN1230187A (zh) 作为蛋白质酪氨酸激酶抑制剂的二环杂芳族化合物
CN1636992A (zh) 喹唑啉类化合物的制备方法
CN1860118A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1675214A (zh) 具有抗增殖活性的嘧啶并化合物
CN1906190A (zh) 选择性激酶抑制剂
CN1404469A (zh) 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CN1625410A (zh) 2,4,6－三氨基－1,3,5－三嗪衍生物
CN1633419A (zh) Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1292789A (zh) 6,9－二取代的2－[反－(氨基环己基)氨基]嘌呤
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
CN1422268A (zh) 5－烷基吡啶并[2,3－d]嘧啶酪氨酸激酶抑制剂
CN1379777A (zh) 氨基－三唑并吡啶衍生物
CN1721397A (zh) 用ω－羧基芳基取代的二苯脲作为raf激酶抑制剂
CN1768058A (zh) 作为黑皮质素受体激动剂的咪唑并吡啶衍生物
CN1433312A (zh) 作为治疗剂的巴比妥酸类似物
CN1922171A (zh) 嘧啶衍生物
CN101031289A (zh) 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物
CN1633436A (zh) 吡咯并嘧啶衍生物
CN1547472A (zh) 作为d-丙氨酰-d-丙氨酸连接酶抑制剂的稠合嘧啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTA MEDICA AG

Free format text: FORMER OWNER: ASTA DRUG COMPANY SHARES

Effective date: 20011221

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20011221

Address after: Frankfurt, Germany

Applicant after: Zentaris GmbH

Address before: Dresden

Applicant before: ASTA Pharma AG.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1031836

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee